• Caesars and MGM Resorts recently experienced a homegrown attack that compromised data and cost each company tens of millions of dollars
• Casinos and other businesses often store data, including names, addresses, and other private information, all of it potentially subject to hacks, in spite of assumed protections
• Sekur Private Data offers a suite of superior protective products, with encrypted emails, secure messengers, and strong communication tools, all utilizing Swiss-based servers designed to safeguard information

The gaming industry in the United States has been shown to be targets of successful cyber-attacks. Two recent attacks against Caesars and MGM Resorts have left the companies paying out tens of millions of dollars to regain control of their systems, leaving patrons’ information vulnerable during the attack (https://ibn.fm/RQmQr). This past week on New to the Street, internationally acclaimed internet privacy expert Alain Ghiai, CEO of Sekur Private Data (CSE: SKUR) (OTCQB: SWISF) (FRA: GTD0), a cybersecurity and internet privacy provider of Swiss-hosted solutions for secure and private communications, and multi-media journalist Ana Berry, discussed the significance of the casino’s stolen data (https://ibn.fm/L9UZS).

According to the segment, the attack occurred from a source within the United States, and the FBI is still investigating the crime. They hypothesize that the hackers are selling the data stolen on the Dark Web. The initial attack appears to have come from an email, and most casinos and other businesses use open-source email platforms, making them more vulnerable to attacks.

Mr. Ghiai said the data is valuable – providing information like names, addresses, hotel stay particulars, and other private information. Even if someone hasn’t recently stayed at one of the casino properties, data from years ago may have been on the servers when the information was stolen.

The single best defense against such threats is a secure email communication platform. Sekur Private Data offers a suite of products with encrypted and private emails, secure messengers, and secure communication tools. The company has chosen Switzerland to locate its data storage because of its neutrality, independence, strong privacy laws, long-standing political stability, and excellent international relations. Switzerland is also home to several large multinational corporations and is ranked as having one of the world’s strongest and most competitive economies.

Sekur’s secure email platform allows management and other C-suite executives a private and secure communication platform. This unique product enables splitting a business domain, allowing emails on Sekur’s platform without limiting the domain’s other emails on other platforms. SekurMail also comes with the SekurSend/SekurReply feature that invites electronic communication on a closed-loop encrypted platform. Even non-subscribers can benefit from the security and privacy features when they receive an email from a Sekur subscriber.

In addition to SekurMail, the company also provides:

• SekurVPN creates a secure, encrypted connection between client’s devices and the internet, giving them access to the web safely and privately by routing their connections through a server and hiding online activities. All data sent and received is hidden from prying eyes.
• SekurMessenger is a Swiss-hosted private and secure messaging communications app providing secure and private chat, self-deleting chat, voice recording, and file transfers via any mobile device, tablet, or desktop computer. All communications are transmitted within Sekur’s secure servers.

Mr. Ghiai reiterated during the show that Sekur wholly owns and controls its Swiss-based servers, never sells data, never mines data, never asks for phone numbers, never uses third-party providers, and never tracks internet traffic. The company offers a 15% savings toward monthly and yearly subscriptions with PROMO CODE: PRIVACY.

You can watch previous episodes of New to the Street or subscribe to stay up-to-date on the newest episodes at https://ibn.fm/nDb14.

For more information, visit the company’s website at www.SekurPrivateData.com.

NOTE TO INVESTORS: The latest news and updates relating to SWISF are available in the company’s newsroom at https://ibn.fm/SWISF

• Prospera Energy recently announced that its sixth horizontal well has commenced drilling
• The well forms part of the company’s phase 2 initiatives, which will see it drill a total of ten horizontal and 8 vertical wells across its Cuthbert and Heart Hill properties
• Recent successes within the program – has seen drilling work and production profiles come in well ahead of expectations – this has prompted Prospera to extend its second phase beyond the initially planned ten horizontal wells
• The company separately revealed that it has reached a production of 1,100 boe/d from its five initial wells as of end October, not including a further 700 boe/d of production currently shut-in to facilitate ongoing developmental work

Prospera Energy (TSX.V: PEI) (OTC: GXRFF) (FRA: OF6B), a public oil and gas exploration, exploitation and development company focusing on conventional oil and gas reservoirs in Western Canada, provided investors and stakeholders with some positive news in recent days (https://ibn.fm/vWRmk). The company announced that its sixth horizontal well had successfully commenced production as of early November, only weeks after announcing the resumption of its horizontal infill drilling program. Prospera have recently launched the second phase of its drilling program, centered around drilling 10 horizontal well locations across its Cuthbert and Hearty Hill properties, with the eventual goal of tripling the company’s daily crude output in 2023.

The company revealed that the initial batch of 5 horizontal wells it had drilled had outperformed its estimated production curve, with the wells’ IP60 (i.e., average daily rate of production after a cumulative 60 days of production) outperforming Prospera Energy’s initial forecasts. With five horizontal wells now in production – and a sixth having recently joined their ranks, albeit not accounted for in the production total – Prospera has seen its gross production swell to 1,100 barrels of oil per day (boe/d). That figure fails to account for 400 boe/d currently halted to accommodate ongoing well development efforts as well as a further 300 boe/d paused to facilitate minor repairs and optimization efforts within the piping network.

With Prospera Energy’s second phase running well ahead of schedule, as well as in an effort to take advantage of currently elevated Western Canadian Select crude prices per barrel, the oil & gas developer have announced plans to extend their initial ten well program, with the development of its light oil slanted wells now set to extended well into the coming year.

Prospera Energy will finance its ongoing activities through its recent debt capital raise, a non-brokered private placement of debt financing which has sought to raise up to $3 million. Proceeds from the financing activity will go towards both, ongoing drilling work as well as to accommodate the company’s joint venture partner deficit; with Prospera’s joint venture partners currently experiencing difficulties, Prospera has assumed total ownership over the project’s costs and foreseeable revenues until the ongoing situation is remedied.

Prospera’s business model has been centered on optimizing hydrocarbon recovery from legacy oilfields using innovative production practices, a production method which has enabled Prospera to both, optimize recovery costs – with less need to carry out exploration and initial drill work – and benefit from modern crude extraction technologies. Similarly, it has allowed the company to bypass issues afflicting peers operating within the realm of the Canadian oil sands space, wherein companies have had to contend with the twin headwinds posed by elevated extraction costs and environmental impact.

With ongoing OPEC-led production cuts, geopolitical concerns, and a potential economic recovery within China likely to maintain crude prices elevated as we go into 2024, Prospera Energy’s rapidly improving crude production profile promises to hold it in good stead going forward.

For more information, visit the company’s website at www.ProsperaEnergy.com.

NOTE TO INVESTORS: The latest news and updates relating to GXRFF are available in the company’s newsroom at https://ibn.fm/GXRFF

• Diamond Lake Minerals is a Utah-based leader in the digital asset and security token space, focused on building and distributing wealth through a smart model that combines holding multiple subsidiaries with targeted STOs (Security Token Offerings)
• A principal element of DLMI’s strategy is to attract traditional investors familiar with buying stock but generally digital asset-avoidant because of their unfamiliarity with new tech alternatives
• DLMI’s subsidiary holdings are based upon building a vertically integrated company that develops enterprises to the point they can become self-sufficient and can eventually be spun off into their own IPOs
• Under the company’s new and growing leadership, its market capitalization has rocketed from around $1 million to over $100 million in less than three months, and its stock jumped during the same period to nearly 12 times its historic value

Multi-strategy operating company Diamond Lake Minerals (OTC: DLMI) CEO Brian J. Esposito highlighted the company’s rapid early growth trajectory during a new interview with the Proactive Investors webcast, pointing out Diamond Lake’s market capitalization jump from “around a million dollars” to over $100 million in just a couple months’ time, and a big stock price increase during that period indicative of investors’ support of the company’s new vision and strategy.

“Multiple subsidiaries is the plan underneath our holdings,” Esposito told webcast host Steve Darling in the interview posted Nov. 20 (https://ibn.fm/DTl58). “The whole idea is wealth preservation, wealth enhancement for our shareholders, get these entities to be performing to their maximum capacity, with the assistance of our advisers and our great experienced management team that we keep adding to our arsenal be able to get these companies very profitable, get them to be extremely self-sufficient, and the idea is to spin them off into their own standalone IPO at some point.”

Each of the subsidiaries will also have a U.S. Securities and Exchange Commission (“SEC”)-registered security token offering (“STO”) designed to appeal to traditional investors who are otherwise unfamiliar with digital assets.

“Now these are the wealth of the world that don’t believe in things like crypto or digital assets or NFTs. They don’t know how to get involved, they’re intimidated by the process, but they know how to buy a stock, so we want to be that stock that they hold in their portfolio to say that they are supporting that industry and they’re actually investing into that space,” Esposito said.

“And the other aspect of it, having a security token offering in the market helps give us more capital to our holdings and it helps open up additional investors around the world to participate in the work that we’re doing,” he added.

DLMI is industry-agnostic, holding and working to acquire enterprises in dozens of sectors ranging from music and entertainment to real estate, healthcare and water accessibility. The company expects to redefine the conglomerate model for the 21st century with a focus on vertical integration, digital securities and sustainable growth.

DLMI will do so by pioneering a hybrid approach to traditional securities and security tokens, positioning itself as an authority in the market and demonstrating how its model can mitigate volatility while drawing in additional capital to support its initiatives and building investor confidence in the process.

In addition, for information on the company’s security token SEC regulated exchange partner INX, and the development of the INX Way, visit https://www.inx.co/inx-ebook/.  This free security token bible, written with the SEC on the rollout of security tokens and the future of digital assets, will greatly deepen your understanding of security tokens.

For more information, visit the company’s website at www.DiamondLakeMinerals.com or LinkedIn page at www.LinkedIn.com/company/Diamond-Lake-Minerals/. 

NOTE TO INVESTORS: The latest news and updates relating to DLMI are available in the company’s newsroom at https://ibn.fm/DLMI

• SuperCom, a global leading provider of traditional and digital identity solutions, just reported a 550% growth in EBITDA and a 74% growth in gross profit margin for Q3 2023
• Gross profit also saw an 89% YOY growth, and revenue YOY increased to $6.8 million from $6.3 million
• Ordan Trabelsi, SuperCom’s President and CEO, attributed impressive performance to the company’s successful execution of its growth strategy

SuperCom (NASDAQ: SPCB), a global leading provider of traditional and digital identity solutions offering advanced safety, identification, and security solutions to governments, just released its financial and operating results for the third quarter of the 2023 financial year (“Q3 2023”). Of note was the 550% growth in EBITDA and a 74% growth in gross profit margins that Ordan Trabelsi, SuperCom’s President and CEO, attributed to the “Successful execution of SuperCom’s growth strategy” (https://ibn.fm/4lm4s).

Revenue for Q3 2023 stood at $6.8 million, up from $6.3 million in Q3 2022. Gross profit saw an 89% year-over-year (“YOY”) growth to $4.0 million from $2.1 million in 2022, while operating income improved by 200% to $0.8 million, up from a $0.8 million operating loss the previous year. For the nine months ending September 30, 2023, SuperCom’s revenue grew by 67%, with gross profit seeing a 66% increase. Non-GAAP operating income also improved to $3.2 million, compared to a $1.1 million loss the previous year.

“A 5-year record net profit, remarkable 550% growth in EBITDA, and 74% growth in gross profit margins are clear indicators of the successful execution of our growth strategy,” noted Mr. Trabelsi.

“The significant increase in the company’s profit margins is driven by the forward momentum we’ve maintained across our projects, where margins typically enhance as projects mature. This trend is an indicator of further potential margin expansion when project timelines align,”  he added.

So far, in 2023, SuperCom’s aggressive expansion has and continues to pay off. Its foray into Europe and North America has seen a significant uptick in product and service adoption, allowing the company to carve out a significant market share and stamp its position as an industry leader. Romania, for instance, submitted a third order to the tune of $3.4 million, with delivery set for Q4 2023. SuperCom also won a $3 million contract to deliver Alcohol Monitoring technologies in California and launched a $3.6 million national EM project in Finland, among others.

“Our steadfast commitment to advancing public safety through technology resonates with governments and agencies worldwide as evidenced by the continued expansion in Finland and our growing partnership with Romania’s Ministry of Interior,” noted Mr. Trabelsi.

“These relationships, underpinned by our cutting-edge technology and reliable services, translate into solid financial performance and increased shareholder value,” he added.

SuperCom looks to build on the current momentum, expand into new markets, and create shareholder value. With its upgraded technological suite, the company has bolstered and continues to bolster its product offering, sharpening its competitive edge and strategic positioning in the global market. With the growing demand for secured electronic monitoring solutions, SuperCom is eyeing potential margin expansion, and its management is optimistic that it will achieve that.

“We are confident that our strategic decisions will further propel us towards achieving our long-term objectives and securing SuperCom’s position as a leader in the industry,” noted Ordan.

For more information, visit the company’s website at www.SuperCom.com.

NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at http://ibn.fm/SPCB

• Sekur signed a major distribution agreement with a distributor in the Hashemite Kingdom of Jordan and The Republic of Iraq to distribute its entire Sekur Swiss-hosted private and encrypted communications platform
• CEO Alain Ghiai is participating in weekly discussions about cybersecurity and internet security on Fox Business TV’s Weekly Sekur Hack of the Week with multimedia journalist Ana Berry to raise awareness of recent cybersecurity threats
• Sekur’s 100% owned Swiss-hosted servers offer closed-loop secure encrypted products, including SekurVPN, SekurMail, SekurMessenger, and other services for businesses, governments, and individuals

Sekur Private Data (CSE: SKUR) (OTCQB: SWISF) (FRA: GTD0), a cybersecurity and internet privacy provider of Swiss-hosted solutions for secure and private communications, recently announced that it has signed a major distribution agreement with a distributor in the Hashemite Kingdom of Jordan and The Republic of Iraq to distribute its entire Sekur Swiss-hosted private and encrypted communications platform. The agreement was signed with Solutions Communications & Security Systems and is valid for 12 months, with renewal options for an additional 12 months. The agreement also covers all of Jordan Iraq, specifically a telecom operator in Iraq called Asiacell Telecommunications Company (https://ibn.fm/TCVF8).

Sekur’s agreement with Jordan and Iraq sheds light on the world’s cybersecurity and internet privacy concerns. To raise awareness on recent cybersecurity issues, the company’s CEO, Alain Ghiai, participates in weekly discussions with New to the Street TV Co-Host/Multimedia Journalist Ana Berry.

The most recent episode discussed how Russians hacked the U.S. Department of Justice and the U.S. Pentagon, stealing about 632,000 email addresses (https://ibn.fm/3PE9P). After an investigation by the U.S. Office of Personnel Management, the source of the cybersecurity breach was a file-share software product called “Move It.” The software had code vulnerabilities that Russian hackers exploited to access the email platform.

Mr. Ghiai explained that many software companies hire 3rd parties to help develop applications, quality controls, and other security features that can be overlooked during development. These 3rd parties often use Big Tech’s open-source software products to create code, which is a furtherance of shortcomings that hackers can find access to a technology platform.

Current geopolitical problems have fueled more frequent bouts of hacking worldwide. Hackers infiltrated Germany’s largest internet service provider, and many believe that Russia was behind this attack because of Germany’s political support for Ukraine. Hackers are taking sides amidst the current war in the Middle East and looking for ways to breach supporting countries.

The best way to limit possible cybersecurity problems is by having separate email accounts, general purpose email, and a private secure platform for sensitive information transmissions. Sekur’s 100% owned Swiss-hosted servers offer closed-loop secure encrypted products, including SekurVPN, SekurMail, SekurMessenger, and other services for businesses, governments, and individuals.

Sometime in 2024, Sekur plans to roll out a new voice encryption service for businesses, another product to help defend against hackers. All of the company’s products have features that have been developed to help significantly diminish cybersecurity hack threats. Sekur uses no third-party technology providers, never asks for phone numbers, does no data mining, never sells data, and controls/owns its servers in Switzerland – a country with the strictest privacy laws in the world.

Sekur’s products are available through subscription, reasonably priced, and easy to use. For a limited time, SekurVPN is available for a 30-day trial, and the company is offering 15% off monthly and yearly fees with Promo Code: PRIVACY.

Stay up-to-date on Mr. Ghiai’s weekly discussions by following New to the Street TV at https://newtothestreet.com/?s=sekur or on the Sekur blog at https://sekur.com/blog/.

For more information, visit the company’s website at www.Sekur.com.

NOTE TO INVESTORS: The latest news and updates relating to SWISF are available in the company’s newsroom at https://ibn.fm/SWISF

• In August 2023, SOHM signed an LOI with CGA Intellectual Holdings Inc. to acquire disruptive stem cell technology and patents
• The company announced in July 2023 it had closed on the needed financing for its various ongoing projects
• SOHM announced in April 2023 it had signed an exclusive distribution agreement for its latest product, the anticonvulsant Levetiracetam
• The company in March 2023 introduced its new topical skincare line of products

SOHM (OTC: SHMN) is a generic pharmaceutical manufacturing and marketing company with a vision of “Globalè Prospèro” (Global Prosperity). SOHM was founded in 1998 and is headquartered in Chino Hills, California.

The company’s primary goal is to create and produce cutting-edge generic medications that span a wide range of treatment areas, all while ensuring top-tier quality and keeping prices affordable. SOHM is dedicated to fully complying with all relevant regulatory prerequisites and upholding the most rigorous industry benchmarks, including the guidelines set forth by WHO-CGMP and USFDA.

Achievements and Milestones

SOHM is a recognized generic pharmaceutical manufacturer, with production and marketing of generic drugs covering all major treatment categories. SOHM also markets innovative formulations and packaging for various therapeutic segments, such as cosmeceuticals, nutraceuticals and OTC oral dosage formulations, with operations spanning India, the Philippines, Uganda, the U.S., the UK and the EU.

SOHM successfully launched a unique and innovative Salic-2 face wash, FōHM by SOHM, during the Oscar after party in Hollywood. The innovative Salic-2 offering in translucent gel form is marketed as an acne medication in the U.S. cosmeceutical market.

With proficiency in both manufacturing and marketing, SOHM stands out. The company holds licenses for producing over 300 products and has established distribution partnerships with firms in the United States, the Philippines and Uganda. Additionally, SOHM’s repertoire includes the launch of an innovative protein supplement, I-Prolec, featuring a distinct composition—a first-of-its-kind in India.

In 2012, SOHM gained recognition as “the most emerging company in the recent past” at the National Integrated Medical Association Conference. The company’s growth was underscored by its inclusion in the roster of ‘Fastest Growing Public Companies’ according to the Orange County Business Journal.

SOHM Today

SOHM brings all of its expertise and market knowledge toward a new vision. The company continues to develop, manufacture and market generic pharmaceutical drugs for various treatment categories. It offers its products in various dosage forms, including tablets and capsules, creams and topicals, ointments and liquids. The company also provides anti-arthritic/analgesics, dermatological drugs, gastrointestinal and respiratory drugs, biotechnology products, anesthetics, immunosuppressive agents and other various treatments. In addition, it offers a skincare line that includes dry dermatoses, mixed skin infection, acne vulgaris and seborrheic dermatitis products.

SOHM markets its products directly and through partner alliance agreements to drug wholesalers, mass merchandisers, chain drug stores and mail-order pharmacies primarily in the U.S. and has previously done business in the Far East, Africa and Southeast Asia. The company is working with its alliance partner in the African continent and Latin American countries.

SOHM has developed a comprehensive marketing strategy encompassing a diverse range of tactics to promote all products. SOHM uses the power of digital marketing channels, social media campaigns and targeted advertising to significantly enhance awareness and recognition of product offerings.

All distribution networks are strengthened through valuable partnerships. SOHM has gained access to the extensive U.S. market through a strategic alliance with different wholesalers catering to C-stores and retailers. The company has likewise partnered with a distribution firm that holds a remarkable network of more than 4,500 independent pharmacy accounts.

Additionally, a strong partnership with a prominent distribution network in New Jersey enables SOHM to facilitate nationwide distribution to big distribution houses, hospitals and retail chain stores which include but are not limited to Walmart, Publix, Sam’s and many more retail giants, thus extending the company’s market presence.

SOHM Long-Term

A report by Grand View Research estimated the global nutraceuticals market at $291.33 billion in 2022 and forecasts expansion at a compound annual growth rate (“CAGR”) of 9.4% from 2023 to 2030. The report states primary factors driving the market growth are preventive health care, increasing instances of lifestyle-related disorders, and rising consumer focus on health-promoting diets. Additionally, increasing consumer spending power in high-growth economies is projected to contribute to the growing demand for nutraceutical products.

Grand View valued the global NSAID market at $19.55 billion in 2021 and forecast it would expand to nearly $30 billion by 2030, marking a CAGR of 5.36% for the period. Projected growth is attributed to factors like the rising prevalence of chronic pain across the world, coupled with a growing global geriatric population. In addition, increasing demand for OTC NSAIDs and the rising adoption of NSAIDs in treating headaches, migraine, toothaches and menstrual pain is expected to boost market growth.

Fortune Business Insights estimated that the global cosmeceuticals market was worth $54.57 billion in 2022 and projects the market will grow to a value of $96.23 billion by 2029, marking a CAGR of 8.4% during the forecast period. The report credits the projected growth to the prevalence of skin disorders around the world and the inclination of dermatologists to prescribe or recommend these products as compared to other treatments.

SOHM envisions a future where it evolves into a prominent global corporation, expanding its reach across international borders while upholding its fundamental core values. The company aspires to extend its export portfolio to encompass 11 countries, showcasing a robust international presence.

Aiming for financial stability, SOHM is committed to maintaining sufficient working capital to support its growth endeavors. The company’s forward trajectory involves strategic collaborations, mergers with diverse brands and a focused approach to business expansion through vertical integration and a balanced mix of organic and inorganic strategies.

In this pursuit, SOHM is dedicated to establishing its proprietary network of partners within the over the counter (“OTC”) sector. Furthermore, the company seeks heightened recognition within crucial therapeutic domains, including oncology, HIV, cardiovascular health, diabetes care and skincare-dermatology, solidifying its prominent standing in these pivotal segments.

Management Team

Baron Night is CEO, President, and Director at SOHM Inc. He has over 40 years of experience in various industries with extensive contacts in emerging markets. His leadership and track record are great assets to the company as SOHM continues to strengthen its position and develop large-scale distribution of generic drug lines.

David Aguilar, Ph.D., is the COO of SOHM. He has 22 years of experience in the pharmaceutical industry, including multiple research positions and scientific publications. He has an extensive background in pharmaceutical Chemistry Manufacturing and Controls (“CMC”), as well as quality assurance experience in preclinical and Investigational New Drug (“IND”) application filings of allogeneic cell-based therapies. He has a deep understanding of regulatory and clinical pathways, coupled with an extensive scientific and technical background in the fields of pharmaceuticals, biopharmaceuticals and gene editing tools research.

Dr. Krishna Bhat, MD PHD, FACC, has a cardiology practice of over 35 years in the field of Clinical and Interventional Cardiology. He is a recipient of the 2021 Hall of Fame Award from the American Heart Association, which was awarded in recognition of his commitment to excellence in the field of Cardiovascular Care through his leadership as an outstanding physician, researcher, and educator. He is also a recipient of the Miles Canada Fellowship Award and the J. Louis Levesque Fellowship Award from Montreal Heart Institute in Montreal, Canada.

Dewey Rushing is a Senior Compliance Remediation and Quality Professional with over 30 years of experience in Quality Assurance and cGMP Compliance for products regulated by the U.S. Food and Drug Administration (“FDA”). He served as a trained Consumer Safety Investigator at the FDA and Instructor at the Los Angeles District. He has in-depth knowledge in technology transfer of biologics and pharmaceutical products, as well as validation of manufacturing equipment, facility cleaning and critical utility systems maintenance. He has an extensive background in auditing GMP facilities, implementing quality systems and performing gap assessments of manufacturing processes and facilities. He has also directed remediation projects in response to federal compliance audit observations.

Sowmya Jacob, MBA-PGP, possesses over a decade of accomplished and evolving expertise in human resources management, along with manufacturing and operations management. She earned an MBA, complemented by advanced marketing certifications. Demonstrating a track record of achievement, she excels in cultivating collaborative work environments and orchestrating transformative changes that lead to heightened productivity. With adeptness in business analysis, she has occupied senior managerial roles, showcasing her mastery. An engaged participant in professional circles, she maintains active memberships in SPHR and CHRP.

For more information, visit the company’s website at www.SOHM.com.

NOTE TO INVESTORS: The latest news and updates relating to SHMN are available in the company’s newsroom at https://ibn.fm/SHMN

• D-Wave third-quarter revenue grew by 51% year-over-year
• D-Wave’s third quarter bookings increased by 53% year-over-year, representing the company’s sixth consecutive quarter of year-over-year booking growth, while the first three quarters bookings increased by 125% when compared to the year earlier period
• CEO Dr. Alan Baratz recently met with Members of Congress to urge them to support the reauthorization of the National Quantum Initiative and ensure that it was expanded to encompass all quantum computing technologies

D-Wave Quantum (NYSE: QBTS), a leader in commercial quantum computing systems, software, and services, recently announced financial results for its fiscal third quarter, which ended September 30, 2023. D-Wave CEO Dr. Alan Baratz believes this is a pivotal moment in quantum computing, as the company leads the industry’s transformative shift from research and developmental experimentation to true delivery of quantum’s enterprise value and utility. “Our annealing quantum computing solutions are driving real business impact today, and we believe that our third quarter results reflect a growing recognition that D-Wave is leading the enterprise quantum wave,” said Baratz (https://nnw.fm/cwuDu). (https://ibn.fm/gUqPU).

Notable third-quarter financial highlights for the company include:

• Growing third-quarter revenue by 51% year-over-year and 50% sequentially from the second-quarter
• A 53% increase year-over-year in D-Wave’s bookings, representing the company’s sixth consecutive quarter of year-over-year booking growth. This brings the company’s year-to-date bookings to $8.4 million, an increase of $4.6 million, or 125% from the corresponding period in 2022
• Working with commercial customers on various new quantum and quantum-hybrid applications spanning customer rewards optimization, radar scheduling for national security, HVAC system design optimization, 6G satellite network optimization, and more

Baratz noted that the company is also seeing customers moving from development to deployment of applications, as they are witnessing first-hand the business impact and advantage that can be achieved using D-Wave’s annealing quantum computing solutions. “That growing commercial success, coupled with our ongoing world-class product development and scientific advancements, reflect, in our opinion, impressive progress across all facets of our business.”

D-Wave’s relentless pursuit of practical quantum computing has resulted in the company’s technology being used today by some of the world’s most advanced enterprises. The company recently initiated an exploration of its quantum technology’s integration with new machine learning areas, including prompt optimization and model training, to potentially bring the power of quantum to artificial intelligence and machine learning for its customers.

In September, Baratz met with Members of Congress to urge them to support the reauthorization of the National Quantum Initiative and ensure that it was expanded to encompass all quantum computing technologies (annealing, hybrid, and gate model). Passage of this legislation could accelerate the development of near-term quantum applications, providing solutions to complex public-sector problems, including optimizing global supply chains, electrical grid resilience, drug discovery, infrastructure, and stability.

SavantX, has used D-Wave’s quantum technology for a variety of projects, including optimization of Pier 300 operations at the Port of Los Angeles – addressing global supply chain strains facing the nation. SavantX CEO Ed Heinbockel said his company was proud to be at the forefront of quantum computing technology, driving innovation and pushing the boundaries of what is possible (https://nnw.fm/gOuPa). (https://ibn.fm/150lf). “Our work on application development to solve real-world problems is a testament to the power of this technology and is better than what classical computers can do alone,” Heinbockel added. “This legislation’s focus on near-term applications and commercialization will be important to push the use of the technology to solve critical public sector problems.”

More customer success stories highlighting D-Wave’s quantum solutions in real-world scenarios can be found at https://nnw.fm/WH4xM. https://ibn.fm/EQ30o.

For more information, visit the company’s website at www.DWaveQuantum.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://nnw.fm/QBTS https://ibn.fm/QBTS

Forward Looking Statements

Certain statements in this press release are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. Forward-looking statements in this press release include, but are not limited to, statements regarding the potential for D-Wave to bring the power of quantum to artificial intelligence and machine learning to its customers and the potential impact of the National Quantum Initiative legislation. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including whether the initiatives set forth in the NQI are implemented and, if so, the success of such initiatives general economic conditions and other risks; the company’s ability to expand its customer base and the customer adoption of its solutions; risks within D-Wave’s industry, including anticipated trends, growth rates, and challenges for companies engaged in the business of quantum computing and the markets in which they operate; the outcome of any legal proceedings that may be instituted against us; risks related to the performance of the company’s business and the timing of expected business or financial milestones; unanticipated technological or project development challenges, including with respect to the cost and/or timing thereof; the performance of the company’s products; the effects of competition on its business; the risk that D-Wave will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk that the company may never achieve or sustain profitability; the risk that the company is unable to secure or protect its intellectual property; volatility in the price of the company’s securities; the risk that its securities will not maintain the listing on the NYSE; and the numerous other factors set forth in D-Wave’s Annual Report on Form 10-K for its fiscal year ended December 31, 2022 and other filings with the Securities and Exchange Commission. Undue reliance should not be placed on the forward-looking statements in this press release in making an investment decision, which are based on information available to D-Wave on the date hereof. D-Wave undertakes no duty to update this information unless required by law.

• MedCana announced in May 2023 full-scale production of non-THC cannabis for export to Europe
• The company earlier in 2023 commenced construction of crop production infrastructure at sites in Central and South America
• MedCana has engaged in talks with the government of Argentina about starting production in that country
• The company in 2023 acquired the assets of Tokan Corp., including an ERP software platform for the cannabis industry

Software Effective Solutions (d/b/a MedCana) (OTC: SFWJ) is a global infrastructure and holding company in the cannabis industry. MedCana currently has five companies focused on pharmaceutical cannabis production, as well a software company focused on managing processes for plant-to-patient operations. The recent acquisition of an irrigation and greenhouse technology company has rounded out MedCana’s portfolio of holdings.

MedCana’s focus is on developing clients and companies in Latin America, initially in Colombia, and partnerships with laboratories, research facilities and hospitals throughout the world. MedCana is building the technology, laboratories, growing facilities and scientific teams to provide premium pharmaceutical-grade cannabis extracts to the world.

MedCana’s goal is to be the world’s premier resource for pharmaceutical cannabis products. The company believes its advantage is its global view and reach. From initial cultivation to final product, MedCana aims to help partners produce pharmaceutical CBD and other extracts that will have no equal.

The company’s mission is to utilize its technology to partner with and develop companies that provide premium pharmaceutical-grade cannabis extracts with absolute integrity, sustainability and social responsibility. MedCana’s team of pharmaceutical scientists includes some of the most respected chemists in the world. They aim to ensure that the company’s customers and partners create premium cannabis extracts that meet the growing worldwide demand. MedCana’s software is designed to ensure traceability and quality from seed to finished product.

MedCana is headquartered in Austin, Texas, with offices in Colombia.

Production

MedCana announced in May 2023 the beginning of full-scale production of non-THC cannabis for export to Europe in response to high demand in that market. This expansion comes after the successful completion of full crop cycle testing and infrastructure development at production sites in Columbia.

The recent acquisition of the assets of Tokan Corp., a software company focused on creating an enterprise resource planning (“ERP”) platform for the cannabis industry, and Eko2O S.A.S., a greenhouse and irrigation engineering company, has positioned MedCana for explosive growth in the region.

As a MedCana subsidiary, Eko2O SA will increase the company’s revenue potential in Central and South America. The subsidiary specializes in the construction and distribution of greenhouses and sophisticated irrigation platforms. A positive outlook has resulted from the company’s expansion as it investigates new opportunities for greenhouse and irrigation system installations in Panama and Uruguay. These opportunities are expected to accelerate Eko2O’s development and strengthen its position as a top supplier of innovative agricultural solutions in cannabis and other sectors that are quickly moving to high technology agricultural production.

In addition, MedCana has started talks with the government in Argentina about possible incentives for beginning operations in that country as part of its ongoing worldwide development strategy. Support from the Argentinean government and the start of new operations there would greatly increase MedCana’s market share in Latin America and solidify the company’s position as the market leader in the cannabis industry.

Market Opportunity

According to a report by Grand View Research, a San Francisco-based market research and consulting company, the global cannabis extract market was valued at $3.5 billion in 2022 and is expected to expand at a CAGR of 20% from 2023 to 2030 to be worth more than $15 billion.

Growing demand for cannabis extracts, including oils and tinctures, and the increased legalization of marijuana for the treatment of different chronic ailments like arthritis, Alzheimer’s, anxiety and cancer are driving the expansion of the industry. The marijuana derivative industry is flourishing due to a greater understanding of its various medical benefits.

Management Team

Jose Gabriel Diaz is CEO of MedCana. He has successfully built, grown and sold multiple telecom companies. He was senior vice president of sales at IP Communications, a national high-speed data provider. He also founded Reallinx, a national data carrier later sold to GTT Communications. Additionally, he is currently president of the A.E.M. Business and Entrepreneurship Association in Austin, Texas.

Claudio Jiménez Cartagena, QF, Ph.D. is Chief Scientific Officer at MedCana. He joined MedCana after working with Sosteli Pharma as Technical Director and serving as a director consultant for the Corporation for Agricultural Industrial Development at the University of Antioquia in Colombia. Before that, he worked as the scientific director at the Institute of Food Science & Technology. He holds a bachelor’s degree in pharmaceutical chemistry, a master’s degree in basic biomedical sciences and a doctoral degree in Environmental Engineering from the University of Antioquia.

Julián Alberto Londoño Londoño, Ph.D., is Senior Vice President of Operations at MedCana. He previously served as general manager for the Corporation for Agricultural Industrial Development, and as Chief Scientific Officer at Sosteli Pharma in the Resource Management Department. He has developed multiple U.S. patents, and recently served as senior advisor to the Secretariat of Agriculture Development for the Government of Antioquia. He holds a doctorate in Chemical Sciences from the University of Antioquia.

For more information, visit the company’s website at www.MedCana.net.

NOTE TO INVESTORS: The latest news and updates relating to SFWJ are available in the company’s newsroom at https://ibn.fm/SFWJ

• Genprex was granted orphan drug designation by the FDA earlier this year for development of REQORSA combined with Tecentriq in small cell lung cancer
• Use of REQORSA combined with Tecentriq is the subject of Genprex’s upcoming Acclaim-3 clinical trial
• Genprex took part in two events in October – the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; and Genprex’s own hosted event, a Virtual Key Opinion Leaders on Bringing Gene Therapy to the Fight Against Lung Cancers

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients living with cancer and diabetes, was granted orphan drug designation (“ODD”) by the US Food and Drug Administration (“FDA”) for its REQORSA(R) immunogene therapy for the combination of its immunogene therapy REQORSA(R) and Genentech Inc.’s Tecentriq(R) as maintenance therapy in patients with extensive stage small cell lung cancer (“SCLC”) who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment earlier this year.

The FDA can grant ODD to a drug or biological product being developed to prevent, diagnose, or treat rare diseases or conditions. The designation is intended to spark innovation among biotech companies developing treatments for the more than 30 million people suffering from rare diseases.

Genprex’s therapy is in development for treating both SCLC and non-small cell lung cancer (“NSCLC”). The company’s Acclaim-1 and Acclaim-2 clinical trials are investigating REQORSA in combination with Tagrisso and Keytruda, respectively, in NSCLC. The company’s Acclaim-3 clinical trial is a Phase 1/2 clinical trial using the combination of immunogene therapy REQORSA(R) and Genentech Inc.’s Tecentriq(R) in patients with extensive stage small cell lung cancer. The Acclaim-3 clinical trial will commence enrollment as soon as reasonably practicable and the company expects this will occur between December 2023 and the end of the first quarter of 2024, subject to the availability of a new manufactured batch of REQORSA.  The Acclaim-1 Phase 2 expansion portion of the trial will also commence enrollment within this time frame, based on the availability of the new REQORSA batch.

“This FDA Orphan Drug Designation, in combination with our recently received FDA Fast Track designation, underscores the great need for better treatment options for patients with ES (extensive-stage)-SCLC and non-small cell lung cancer,” said Rodney Varner, Genprex president, chair, and CEO (https://ibn.fm/n3GXo). “We look forward to initiating the Acclaim-3 clinical trial in order to bring hope of an effective new therapy to patients suffering with this life-limiting cancer.”

Genprex recently took part in two events in October – the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; and Genprex’s own hosted Virtual Key Opinion Leader (“KOL”) Event on Bringing Gene Therapy to the Fight Against Lung Cancers. Each event provided Genprex the opportunity to present its findings in the respective areas.

• 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Genprex presented data on using REQORSA to treat lung cancers (https://ibn.fm/5YzLY). The company presented that the Acclaim-1 Phase 1 study had no dose-limiting toxicity, established a Phase 2 recommended dose, and demonstrated evidence of efficacy of REQORSA in combination with Tagrisso(R). The company’s research collaborators also presented preclinical results showing that REQORSA in combination with a checkpoint inhibitor has anti-tumor activity in a humanized mouse model of SCLC.
• These data and more were highlighted in the company’s recent KOL event: Bringing Gene Therapy to the Fight Against Lung Cancers. The event discussed REQORSA as a potential treatment for NSCLC and SCLC (https://ibn.fm/FnuDk).

The American Cancer Society estimates that almost 127,000 people will die from lung cancer this year, making it one of the most lethal cancers in men and women. SCLC comprises approximately 13% of all lung cancer diagnoses, while NSCLC represents approximately 84% of lung cancer diagnoses (https://ibn.fm/R3mLE). There is currently an unmet need for treatment, which Genprex is on a mission to address.

The company’s oncology pipeline aims to reprogram the course of cancer. The company is evaluating its proprietary, non-viral ONCOPREX(R) Nanoparticle Delivery System, a systemic gene therapy delivery system used in clinical trials for human cancer. It is currently being evaluated in several trials.

For more information, visit the company’s website at www.Genprex.com.

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

• Clene is focused on developing and commercializing novel clean-surfaced nanotechnology (“CSN(R)”) therapeutics
• The company utilizes an electro-crystallization nanotherapeutics platform, which results in nanocrystals that exhibit catalytic activities multiple times higher than numerous other commercially available nanoparticles that the company has comparatively evaluated
• Clene is focusing on central nervous system (“CNS”) disorders like amyotrophic lateral sclerosis (“ALS”), multiple sclerosis (“MS”), and Parkinson’s disease (“PD”)
• Its lead investigational product, CNM-Au8(R), has so far demonstrated a good safety and tolerability profile, with Phase 2 trials suggesting efficacy in ALS patients

Nanotechnology has attracted a great deal of the scientific community’s attention thanks to its ability to deliver medicinally attractive nanoparticles (“NPs”) with promising performances that are directly attributable to such properties as ease of cellular uptake, stability, solubility, synthetic accessibility, and release pattern and cell penetration.

Studies investigating the therapeutic capabilities of metallic NPs such as selenium, silver, and gold, as well as metallic oxides like zinc oxide and aluminum oxide, have documented their potential anti-diabetic, antibacterial, antiviral, and antiparasitic capabilities (https://ibn.fm/OwfF4). Moreover, metallic nanoparticles have been known to have remarkable catalytic activity due to their large surface-area-to-volume ratio compared to the bulk material. This property has led to the development of therapeutic candidates, with Clene (NASDAQ: CLNN), a clinical-stage pharmaceutical company, leading the way.

Clene’s efforts date back to 2013 when the company innovated an electro-crystallization nanotherapeutics platform. The innovation led to the development of novel clean-surfaced nanotechnology (“CSN(R)”) therapeutics that, the company explains (https://ibn.fm/bWoqv), “are comprised of atoms of transition elements that, when assembled in nanocrystal form, possess unusually high, unique catalytic activities not present in those same elements in bulk form.” In fact, Clene underlines that its platform results in nanocrystals that exhibit catalytic activities multiple times higher than numerous other commercially available nanoparticles that the company has comparatively evaluated.

The catalytic activities, the company notes, drive, support, and maintain beneficial metabolic and energetic cellular reactions within diseased, stressed, and damaged cells and have influenced the development of multiple drug candidates, including its lead investigational product, CNM-Au8. The company is currently focusing its efforts on addressing the high unmet medical needs related to CNS disorders like ALS, MS, and PD, conditions that cumulatively affect more than 1.4 million people in the U.S.

CNM-Au8 is a highly concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals that has been the subject of multiple non-clinical studies and clinical trials. Non-clinical toxicology studies, for instance, have demonstrated no adverse effect levels, even when the maximum feasible dosing levels were orally administered. Moreover, in vitro and in vivo pharmacology studies have demonstrated that CNM-Au8 treatment improves neuroprotection and generation of new myelin sheaths around axons of the adult CNS in multiple models of ALS, MS, and PD.

“A Phase I first-in-human study did not reveal safety or tolerability concerns for CNM-Au8 in healthy human volunteers. Similarly, no significant safety signals have been identified across all completed Phase 2 clinical trials in ALS, MS, and PD populations. Two Phase 2 clinical trials in ALS (RESCUE-ALS and the HEALEY ALS Platform Trial) suggested efficacy signals without any significant safety findings,” wrote the company in its 2022 annual report (https://ibn.fm/G8U37).

This September, Clene released long-term follow-up data for patients treated with CNM-Au8 for up to 133 weeks in the open-label extension (“OLE”) of the HEALEY ALS Platform Trial. These results showed significantly improved survival compared to matched placebo controls obtained from the Pooled Resource Open-Access ALS Clinical Trials (“PRO-ACT”) database, the largest U.S. clinical database of previous ALS trials. The follow-up analysis also pooled data from both the HEALEY ALS Platform Trial and the RESCUE-ALS trial, revealing that patients originally randomized to the CNM-Au8 30mg dose demonstrated a statistically significant 59% decreased risk of death compared to matched placebo patients.

“To show such profound survival improvement using the HEALEY ALS Platform Trial dataset alone and a pooled HEALEY and RESCUE dataset is remarkable, and helps confirm the survival benefit seen in the prespecified secondary endpoint. Clene is extremely gratified to see this consistent long-term survival data from the HEALEY ALS Platform Trial OLE, with a continued clean safety profile, adding to the totality of survival evidence,” Benjamin Greenberg, M.D., Head of Medical at Clene, stated in the press release announcing the results of the follow-up analysis (https://ibn.fm/kdskE).

Clene is the sole inventor of its CNS therapeutic drug candidates, as well as the candidates’ manufacturing processes and methods of use. These inventions are protected by a comprehensive intellectual property portfolio of over 150 patents issued worldwide, with about 20 additional patents pending, as of December 31, 2022. The IP portfolio provides a solid foundation for the company‘s planned commercialization of its CSN therapeutics subject to U.S. Food and Drug Administration (“FDA”) approval.

For more information, visit the company’s website at www.Clene.com.

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN